埃迪魯單抗(INN:eldelumab;開發代號:BMS-936557[1])或譯依德魯單抗,是一種抗CXCL10全人單株抗體(IgG1 κ型)[2][1],設計用於治療克羅恩病和潰瘍性結腸炎。[3]
該藥物由百時美施貴寶和Medarex開發。[4]
參考資料[編輯]
- ^ 1.0 1.1 Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, et al. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. Journal of Crohn's & Colitis. April 2016, 10 (4): 418–28. PMC 4946756 . PMID 26721935. doi:10.1093/ecco-jcc/jjv224.
- ^ Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs. www.creativebiolabs.net. [2017-03-24].
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
- ^ Eldelumab. AdisInsight. Springer Nature Switzerland AG.